Failure of omalizumab treatment after recurrent systemic reactions to bee-venom immunotherapy.
Allergy Section, General University Hospital of Alicante, Alicante, Spain. soriano_vic@gva.es
V
V
Soriano Gomis
P
P
Gonzalez Delgado
E
E
Niveiro Hernandez
D000328:Adult; D000818:Animals; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001514:Bee Venoms / Q000276:immunology*; D001516:Bees; D003888:Desensitization, Immunologic; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000276:immunology / Q000628:therapy*; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D000069444:Omalizumab
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001514:Bee Venoms; D000069444:Omalizumab; D007073:Immunoglobulin E